CSPC Pharmaceutical Group (HKG:1093) said China's National Medical Products Administration (NMPA) granted new drug registration approval to Aprepitant Injection, according to a Monday filing with the Hong Kong bourse.
Aprepitant Injection is a submicron emulsion injection of a neurokinin-1 (NK1) receptor antagonist. It is aimed at preventing nausea and vomiting with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) in adult patients.
The company's stocks were down by 2% in recent trading.
Price (HKD): $4.57, Change: $-0.090, Percent Change: -1.93%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。